Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05688670 · ClinicalTrials.gov registry record · Phase 4
Regional Anesthesia Following Pediatric Cardiac Surgery
A Phase 4 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
NCT05688670: Completed Phase 4 study, sponsored by Duke University.
NCT05688670 is a Phase 4 study that has completed, run by Duke University. The registered enrollment target is 52 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05688670, a Phase 4 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate pain control following pediatric cardiac surgery with the use of local anesthesia via an ultrasound guided regional anesthetic technique compared with surgeon delivered wound infiltration.
Primary Outcome
Postoperative opioid medication expressed in morphine equivalents per kilogram
Interventions
- DRUG Ropivacaine 0.2% Injectable Solution
- PROCEDURE Regional Anesthesia
- PROCEDURE Wound infiltration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2023-03-29 |
| Est. Completion | 2025-01-22 |
| Phase | Phase 4 |
What the finished NCT05688670 record still lists
NCT05688670 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 3 interventions - of which Ropivacaine 0.2% Injectable Solution is the first listed.
NCT05688670 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05688670 about?
NCT05688670 is a clinical study titled "Regional Anesthesia Following Pediatric Cardiac Surgery". The purpose of this study is to evaluate pain control following pediatric cardiac surgery with the use of local anesthesia via an ultrasound guided regional anesthetic technique compared with surgeon delivered wound infiltration.
What is the current status of trial NCT05688670?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2023-03-29. Estimated completion is 2025-01-22.
What interventions are being tested in trial NCT05688670?
The interventions under investigation include: Ropivacaine 0.2% Injectable Solution (DRUG), Regional Anesthesia (PROCEDURE), Wound infiltration (PROCEDURE).
Who is sponsoring clinical trial NCT05688670?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05688670's enrollment target sits among peer trials
52 1233rd of 2000 higher than 752 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI